ArticleHealth science reports2025
Drug History and SLE Laboratory Findings Among Iraqi Patients: A Hospital-Based Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Systemic lupus erythematosus (SLE) is a recurrent and remitting autoimmune disease that affects many organ systems. It is more common in women of reproductive age, with a 9:1 female preponderance. Due to the lack of data from developing countries, our study aims to provide comprehensive insights into the drug history and SLE laboratory findings among Iraqi patients. Methodology: It is a cross-sectional study at the Baghdad Medical Complex in Iraq. All SLE patients who attended the outpatient clinic between September and December 2022 were included. The patients included those who came for follow-up, deterioration of their symptoms, or a first-time diagnosis. Results: SLE is much more prevalent among female patients. The ratio of female and male patients in our study was 19:1. This disease is more prevalent in the reproductive age group, with the mean age of our patients being 34 years, although the range spans from 15 to 85 years. The most prevalent signs and symptoms among the patients were photosensitivity (79.5%), hair loss (74%), and malar rash (72.5%). Most patients had positive antinuclear antibodies and anti-double-stranded DNA antibodies, with 73.5% and 65% testing positive, respectively. Conclusion: In conclusion, this study represents an important step in exploring SLE within Iraq, providing invaluable insights into its management and laboratory findings. The findings contribute to the global understanding of SLE. This study underscores the significance of Iraq's genetic backgrounds and environmental conditions, which are different from those of other countries, in the process of enhancing the global medical literature and expanding our understanding of SLE patterns around the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.